Drug Profile
Research programme: cancer therapeutics - Taiho Pharmaceutical
Alternative Names: HM05; TAS-2913; TAS-2985; TAS0286Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Aurora kinase A inhibitors; Epidermal growth factor receptor antagonists; Fibroblast growth factor receptor antagonists; HSP90 heat-shock protein inhibitors; Proto oncogene protein c-akt inhibitors; Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported B-cell lymphoma; Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in B-cell lymphoma in Japan (PO)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in Japan
- 16 Apr 2018 Taiho Pharmaceutical and Helsinn agree to co-develop TAS 0286/HM 05 for Non-small cell lung cancer